201 related articles for article (PubMed ID: 25537514)
1. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
Gu Y; Zhang M; Peng F; Fang L; Zhang Y; Liang H; Zhou W; Ao L; Guo Z
Oncotarget; 2015 Feb; 6(4):2397-406. PubMed ID: 25537514
[TBL] [Abstract][Full Text] [Related]
2. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome Patterns of
Arakelyan A; Melkonyan A; Hakobyan S; Boyarskih U; Simonyan A; Nersisyan L; Nikoghosyan M; Filipenko M; Binder H
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525353
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
5. Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients.
Pastrello C; Polesel J; Della Puppa L; Viel A; Maestro R
Carcinogenesis; 2010 Dec; 31(12):2124-6. PubMed ID: 20810544
[TBL] [Abstract][Full Text] [Related]
6. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].
Gorodnova TV; Maksimov SIa; Guseĭnov KD; Imianitov EN
Vopr Onkol; 2014; 60(3):339-42. PubMed ID: 25033687
[TBL] [Abstract][Full Text] [Related]
9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA signatures in hereditary breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
[TBL] [Abstract][Full Text] [Related]
12. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
13. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
14. Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2.
Guo L; Peng Y; Meng Y; Liu Y; Yang S; Jin H; Li Q
Oncotarget; 2017 Sep; 8(40):68483-68492. PubMed ID: 28978132
[TBL] [Abstract][Full Text] [Related]
15. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
[TBL] [Abstract][Full Text] [Related]
16. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
17. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
[TBL] [Abstract][Full Text] [Related]
20. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
